Drug intelligence / Profile preview

JY29-2

Development stage: Unknown
Lead developer: Jiuyuan Gene Engineering
Modality: Peptides
Administration: Subcutaneous

Overview

JY29-2 is a semaglutide biosimilar developed by Hangzhou Jiuyuan Gene Engineering Co., Ltd. It is a peptide biologic that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. The drug is specifically formulated as a refillable/extended injection for the treatment of obesity and overweight, where it is branded as Jikeqin (吉可亲). By mimicking the action of endogenous GLP-1, JY29-2 stimulates insulin secretion, inhibits glucagon release, and slows gastric emptying, thereby regulating appetite and caloric intake. As of early 2024, the drug has received IND approval in China for weight management and is progressing toward Phase III clinical trials.

Brand names: Jikeqin吉可亲
Other names: semaglutide biosimilar可充填延续注射

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on JY29-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JY29-2.

Explore the full profile